Opioid Use Disorder Market Forecasts from 2023 to 2028

The opioid use disorder market is estimated to grow at a CAGR of 8.71% during the forecast period.

The continuous use of opioids that results in clinically significant distress or impairment is referred to as opioid use disorder. Opioid use disorder is characterized by an overwhelming need to use opioids. Hence, dependency and addiction are features of the most severe kind of opioid use disorder. Opioid use disorder includes serious side effects that might result in impairment, relapses, and even death.

Market Drivers:

Growth chronic disease is driving the market growth

The rise in the incidence of chronic diseases including cancer, cardiovascular, and Orthopaedic diseases is primarily driving the opioid use disorders market growth. The incidence of surgical intervention rises as the number of chronic conditions increases. After surgery, opioid medications are used to alleviate pain. Even when the pain has subsided, this component can still lead to opiate drug addiction. Thus, the predicted increase in the frequency of chronic illnesses drives up demand for medications to treat opioid use disorders and propels the expansion of the opioid use disorder market.

Increase in awareness and overall financing

In the upcoming years, it is anticipated that the market dynamics for opioid use disorders will alter. The repeal of the DATA 2000 waiver and the limit on the number of patients that a doctor may treat with buprenorphine would completely alter the opioid use disorder market environment in the US and increase the usage of buprenorphine in the treatment environment. Additionally, it is anticipated that future legislative changes will increase patients with opioid use disorder access to MOUD and their usage in therapeutic settings.

Growing counselling and behavioral treatment

An evidence-based treatment for those with opioid use disorders is medication for opioid use disorder (MOUD), which is regarded as the gold standard of opioid use disorder treatment. In addition to medication, counseling, and behavioral treatments may be crucial components of opioid use disorder treatment, but they do not work by themselves. Additionally, medications are used to reduce cravings, lessen withdrawal symptoms, and avoid the euphoric effects of opioids. These medications enhance safety and lessen withdrawal symptoms, which may cause relapse or continued drug use but do not "cure" the sickness. Three FDA-approved medications are frequently used to treat opioid use disorders: methadone, buprenorphine, and naltrexone.

Increasing cases of opioid addiction

The general population is currently afflicted by a wide range of severe and chronic diseases, such as cancer, cardiovascular disease, pain from accidents, and other maladies. Patients who suffer from these illnesses commonly have chronic pain, which is typically managed with drugs, especially opioids. While the pain lessens, there is a greater chance that the patient may develop drug dependence. As a result of their abrupt discontinuation and growing dependency on certain drugs, the patient could experience withdrawal symptoms. This is the major growth driver for the opioid use disorder market.

Growing self-help programs

Self-help programs like Alcoholics Anonymous and Narcotics Anonymous are advocated for those with substance use problems, and these are anticipated to propel the opioid use disorder market growth. The integration of education, motivational enhancement, and self-help groups into individual and group counselling techniques in inpatient and outpatient programs aids patients in changing their perspectives on how opioids affect their lives, realizing that change is possible, and working to reduce behaviours that support illicit drug use while developing new behaviours that lessen drug-related problems.

Opioid treatment programs

The treatment services provided by opioid treatment programs (OTPs) are covered by Medicare and all state Medicaid programs. Using the code H0020 (Alcohol and/or drug services; methadone administration and/or service (supply of the drug by a licensed program), state Medicaid programs often pay for OTP services in daily or weekly bundles that include methadone doses, toxicology testing, nurse services, and counselling. Medicaid covers around 40% of all non-elderly individuals with opioid use disorder (OUD). These treatment programs are anticipated to propel the opioid use disorder treatment market.

North America is anticipated to dominate the opioid use disorder market

During the projected period, the North American opioid use disorder treatment market is anticipated to have a significant market share. The number of OWS diagnoses and treatments is rising steadily in the United States. The main causes of the rising use of opioids for the treatment of pain are chronic disorders, which are becoming more common. Additionally, big market participants like Indivior get the majority of their income from the American market.

Key manufacturers are focusing on product innovation

The top players in the opioid use disorder (OUD) market consistently choose effective tactics to strengthen their brand equity and foster the expansion of the worldwide market. Acquiring rival businesses and securing a profit for both entities is one such effective technique. For instance, Orexo AB worked with ApexB.io and Magellan Rx Management in February 2021 to do more studies using Modia.

Leading organizations working on the development of novel opioid use disorder medications include Braeburn Pharmaceuticals, BioXcel Therapeutics, MediciNova, and others. These medications may become available which is propelling the opioid use disorders market growth in the upcoming years.

Market Key Developments

• In May 2023, For BRIXADI (buprenorphine) extended-release subcutaneous injection for moderate to severe opioid use disorder, Braeburn submitted a revised NDA, which the FDA accepted.
• In May 2023, according to Trevena, Inc., OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved by the FDA in the United States for use in adults to manage acute pain severe enough to require an intravenous opioid analgesic, has been accepted by China's National Medical Products Administration (NMPA).

Segmentation:

By Drug Type

• Buprenorphine
• Methadone
• Naltrexone
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Offline
• Online

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others